Synsorb Pk endotoxin neutralizer data

SYB presented Phase II data from 364 children with suspected E. coli infections, showing a 52 percent reduction in relative risk of hemolytic uremic syndrome in patients treated with Synsorb Pk within three days of symptom onset. The treatment was a seven-day regimen and was carried out in children who had uncomplicated gastroenteritis. A relative risk reduction of 34 percent was noted overall for the active treatment in the placebo-controlled, double-blind trial. ...